Previous clinical studies have shown that cabozantinib toxicity, which mainly manifests as diarrhoea, nausea, fatigue, decreased appetite, hand–foot syndrome and hypertension is due to the direct inhibition of VEGFR, FLT3 and KIT kinases, primary cabozantinib targets.67 This evidence concerns the gene KIT and hypertensive disorder.